ARTELIS BIO IS DEVELOPING FIRST IN CLASS ANTIBODY DRUG CONJUGATES FOR THE TREATMENT OF T CELL NON-HODGKIN LYMPHOMAS AND LEUKEMIAS

The Girardi Lab at Yale has identified and validated TCR-Vβ2 as a novel T cell target with strong potential for therapeutic development, including ADCs, to treat T cell malignancies. In matched patients, TCR-Vβ2 is highly and selectively expressed on all malignant T cells while appearing on less than 5% of healthy cells, offering significantly greater selectivity than current tumor antigens. With a vision to establish a new standard of care for rare and poorly treated T cell leukemias and lymphomas, the lab has developed a humanized anti-TCR-Vβ2 antibody that has demonstrated efficacy in vitro and in vivo and is now poised for integration into a novel ADC program.

Artelis Bio, which plans to license this state-of-the-art technology, was founded in 2024 and is actively raising a pre-seed financing round to propel this innovation toward clinical application.